Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03204929
Recruitment Status : Completed
First Posted : July 2, 2017
Last Update Posted : March 17, 2020
Information provided by (Responsible Party):
Collaborative Medicinal Development Pty Limited

Brief Summary:
Multicenter, open-label dose-escalation study

Condition or disease Intervention/treatment Phase
Parkinson Disease Drug: Cu(II)ATSM Phase 1

Detailed Description:

Multicenter, open-label, phase 1 study of Cu(II)ATSM administered orally to patients with early idiopathic Parkinson's disease. The study will be conducted in two phases. In the first phase, dose cohorts of six patients each will receive escalating daily doses of Cu(II)ATSM to establish the recommended phase 2 dose (RP2D). The starting dose will be 12 mg/day, which has been shown to be well tolerated in an ongoing phase 1 pharmacokinetic and dose-finding study of Cu(II)ATSM in patients with ALS ( identifier NCT02870634). In the second phase of the study, an expansion cohort of 20 patients will be treated at the RP2D to confirm tolerability and assess preliminary evidence of efficacy.

In both the dose escalation and expansion cohorts, once the first 28 days of treatment are completed, at the discretion of the investigator a patient may continue to receive Cu(II)ATSM treatment for a maximum of six 28-day treatment cycles.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's Disease
Actual Study Start Date : August 14, 2017
Actual Primary Completion Date : November 30, 2019
Actual Study Completion Date : February 29, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Cu(II)ATSM
Cu(II)ATSM dosed once daily
Drug: Cu(II)ATSM
copper-containing synthetic small molecule
Other Name: diacetylbis(N(4)-methylthiosemicarbazonato) copper(II)

Primary Outcome Measures :
  1. Recommended phase 2 dose [ Time Frame: 6 months ]
    Recommended phase 2 dose as determined by the number of patients in each dose cohort with intolerance over up to six months treatment

Secondary Outcome Measures :
  1. Treatment-related changes in disease severity [ Time Frame: 6 months ]
    Treatment-related changes in disease severity assessed by the Unified Parkinson Disease Rating Scale (UPDRS)

  2. Treatment-related changes in motor function [ Time Frame: 6 months ]
    Treatment related changes in motor function assessed by the UPDRS Part III score and UPDRS ambulatory capacity subscore

  3. Treatment-related changes in cognitive function [ Time Frame: 6 months ]
    Treatment related changes in cognitive function assessed by the Montreal Cognitive Assessments (MoCA)

  4. Treatment-related changes in quality of life [ Time Frame: 6 months ]
    Treatment related changes in quality of life assessed by the 39-item Parkinson Disease Questionnaire (PDQ-39)

  5. Treatment-related changes in constipation [ Time Frame: 6 months ]
    Treatment related changes in constipation assessed by the Wexler Constipation Score

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent prior to initiation of any study-specific procedures
  • Early idiopathic Parkinson's disease (PD) with at least two of the cardinal signs of PD (resting tremor, bradykinesia, rigidity, postural instability). If tremor is not present, must have unilateral onset and persistent asymmetry of symptoms.
  • Hoehn & Yahr stage ≤ 2
  • First PD motor symptoms occurred ≤ 5 years prior to screening visit
  • Use of dopaminergic therapy allowed provided dose is stable for at least 8 weeks prior to screening visit
  • Use of amantadine and/or anticholinergics allowed provided dose is stable for at least 8 weeks prior to screening visit
  • Use of CNS-acting medications allowed provided dose is stable for at least 4 weeks prior to screening visit
  • Age ≥ 30 years at time of PD diagnosis
  • Adequate bone marrow reserve, liver and renal function:

Absolute neutrophil count ≥ 1500/µL; Platelet count ≥ 150,000/µL; Hemoglobin ≥ 11 g/dL; Creatinine clearance ≥ 6- mL/min (Cockroft & Gault formula); ALT and/or AST ≤ 2 x ULN; total bilirubin ≤ 1.5 x ULN; albumin ≥ 2.8 g/dL

  • Women and men with partners of childbearing potential must take effective contraception while on study and women of childbearing potential must have a negative pregnancy test and be non-lactating at screening

Exclusion Criteria:

  • Atypical Parkinsonism
  • Taking ≥ 3 dopaminergic medications
  • Exposure to typical or atypical antipsychotics or other dopamine blocking agents within 6 months prior to screening visit
  • Exposure to any other investigational agent within 6 months or 2 investigational agents within 12 months prior to screening visit
  • Known immune compromising illness or treatment
  • History of brain surgery for PD, including deep brain stimulation and stem cell transplants
  • History of cognitive or neuropsychiatric conditions
  • Inability to swallow oral medications or presence of a GI disorder (eg, malabsorption) deemed to jeopardize intestinal absorption of study drug
  • Active GI disease (excluding GERD) within 30 days prior to screening visit
  • Presence of any of the following clinical conditions:

any significant non-PD CNS disorder; drug abuse or alcoholism; unstable cardiac, pulmonary, renal, hepatic, endocrine or hematologic disease; active infectious disease; AIDS or AIDS-related complex; malignancy within 3 years of screening (other than fully excised non-melanoma skin cancer, cured in situ cervical carcinoma, early stage bladder cancer, or DCIS of breast); psychosis or untreated major depression within 30 days of screening; dementia

  • Current use of strong inducers or inhibitors of CYPs 2C19 and 2D6

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03204929

Layout table for location information
Australia, New South Wales
Macquarie University
Macquarie Park, New South Wales, Australia, 2109
Australia, Victoria
The Royal Melbourne Hospital
Melbourne, Victoria, Australia, 3050
Sponsors and Collaborators
Collaborative Medicinal Development Pty Limited
Layout table for investigator information
Principal Investigator: Andrew Evans, MD Melbourne Health
Layout table for additonal information
Responsible Party: Collaborative Medicinal Development Pty Limited Identifier: NCT03204929    
Other Study ID Numbers: CMD-2016-002
First Posted: July 2, 2017    Key Record Dates
Last Update Posted: March 17, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Plan to publish trial results and post results on

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Trace Elements
Physiological Effects of Drugs